Latest / The Best of the Money Show / Aspen reports 28% earnings growth as R28bn APAC sale strengthens balance sheet
Transcript
- 0:00Speaker 1: Aspen Pharmacare saying today it's normalized earnings from continuing operations
- 0:03Speaker 1: up nearly 28% in the year to the end of June.
- 0:07Speaker 1: Investing heavily in producing the GLP weight loss medications. Sean
- 0:11Speaker 1: Capazario is the chief financial officer at the Aspen Group. Sean,
- 0:17Speaker 1: good evening. Your commercial pharmaceutical segment, your revenues there were
- 0:20Speaker 1: up 5% mainly because of strong demand for the weight
- 0:24Speaker 1: loss drug Monjaro. I mean, that demand, I presume, is
- 0:28Speaker 1: really very strong at the moment.
- 0:31Speaker 2: Yes, good evening, Stephen and listeners. It is very strong.
- 0:35Speaker 2: You'll remember that last year, I think we finished the
- 0:38Speaker 2: year just around 300 million off turnover and we targeted
- 0:42Speaker 2: to do more than a billion this year and we
- 0:45Speaker 2: have exceeded a billion rand and we've got more than
- 0:47Speaker 2: a 50% market share of the GLP-1 market. So it's
- 0:52Speaker 2: done very well and demand is strong and growing.
- 0:56Speaker 1: We've seen quite a lot of copycats, I mean, fake
- 0:59Speaker 1: versions of GLP drugs. Do you believe government is doing
- 1:02Speaker 1: enough to stop that? I mean, they would hurt you
- 1:04Speaker 1: if they're allowed to get going again?
- 1:07Speaker 2: Yeah, look, there's two types there. There's what you call
- 1:10Speaker 2: the compounders, and I think those are the guys that
- 1:13Speaker 2: are using semi-legitimate, just haven't been approved, and those have
- 1:18Speaker 2: been clamped down. I think the one that is still
- 1:20Speaker 2: out there is the actual counterfeit drugs where they're coming in,
- 1:23Speaker 2: no one knows where. where they come from and what
- 1:27Speaker 2: the efficacy is. And that is an area that I
- 1:29Speaker 2: think government is starting to take seriously, but still a
- 1:33Speaker 2: lot of work to do there. There's a lot of
- 1:34Speaker 2: counterfeit product out there, not just in weight loss, in
- 1:37Speaker 2: all medications.
- 1:39Speaker 1: And I mean, the prices of weight loss drugs, there's
- 1:41Speaker 1: huge public interest in this, as you can imagine. Do
- 1:44Speaker 1: you see the price coming down quite quickly? I mean,
- 1:46Speaker 1: more generics are going to come onto the market now.
- 1:48Speaker 2: Yeah, look, I think with generics coming on, so bearing
- 1:51Speaker 2: in mind that generics will be generics of what they
- 1:55Speaker 2: call the semaglutide molecule. Our molecule at the moment is
- 1:58Speaker 2: a 2-zepatide, so it's a different molecule, but the The
- 2:02Speaker 2: semaglutide molecule originator products on the market are those MPEGs,
- 2:05Speaker 2: and so the generics of those are coming. We've got
- 2:08Speaker 2: one in for registration as well, and I think we
- 2:10Speaker 2: estimate that pricing will at least be half of the
- 2:14Speaker 2: originator pricing, and as more competitors come in, there could
- 2:17Speaker 2: be some further pricing opportunity there. I think people... are
- 2:23Speaker 2: looking for a more affordable product in that area. And
- 2:27Speaker 2: so this could be an opportunity to really grow the
- 2:29Speaker 2: market for us and other generic competitors.
- 2:33Speaker 1: Weight loss is a major issue in our society and
- 2:35Speaker 1: related to that is diabetes. You've got the human insulin
- 2:39Speaker 1: manufacturing contract started in May. What impact are you expecting
- 2:43Speaker 1: that to have over the longer term for you?
- 2:46Speaker 2: Yeah, that's one of the drivers. If you look to
- 2:49Speaker 2: our guidance for next year, it is partly one of
- 2:52Speaker 2: the drivers for the growth in our manufacturing profits next
- 2:55Speaker 2: year as we get those volumes in for a full
- 2:58Speaker 2: 12 months. This year, we only had it in for
- 3:01Speaker 2: probably around a month or so. So that will drive
- 3:03Speaker 2: quite a lot of energy. And I think it's a
- 3:08Speaker 2: well-needed product. in the tender market, so we'll be making
- 3:11Speaker 2: that for our customer. So that's a very important one
- 3:15Speaker 2: for us, for our volumes in the South African factory.
- 3:18Speaker 1: You talked today about the new sterile finished dose factories
- 3:22Speaker 1: or manufacturing facilities, I think is the phrase you use.
- 3:25Speaker 2: That's right.
- 3:26Speaker 1: Here and in France. What are you expecting from them?
- 3:29Speaker 1: I mean, you're clearly very optimistic they're going to make
- 3:32Speaker 1: a major change.
- 3:34Speaker 2: Yeah, you'll recall last year, Stephen, we lost that contract
- 3:37Speaker 2: contract in France and that set us back quite a lot.
- 3:41Speaker 2: So we had to go back and look at our
- 3:43Speaker 2: model and what we did then is we said we
- 3:45Speaker 2: need to bring our cost base down to match the
- 3:47Speaker 2: contracts that we have. And so we've gone through a
- 3:49Speaker 2: major reshaping in both the French sterile facility and our
- 3:54Speaker 2: South African sterile facility where the human insulins are being made.
- 3:57Speaker 2: And so we've got the benefit of those partly in
- 4:00Speaker 2: this year as we've driven those cost savings through and
- 4:04Speaker 2: the reshaping is almost complete. Obviously, next year you're going
- 4:07Speaker 2: to have a full 12-month benefit of the cost savings.
- 4:10Speaker 2: You're also going to have increased volumes coming from the
- 4:12Speaker 2: human insulin. And then also we've seen a nice uptick
- 4:16Speaker 2: in volumes in our French facility as the whole tariff.
- 4:19Speaker 2: You'll recall last year there was also a lot of
- 4:21Speaker 2: noise on tariffs and our customers, they weren't wanting to
- 4:25Speaker 2: put extra volume into the facility. That tide has turned.
- 4:29Speaker 2: So we've seen volumes growing in our French facility and
- 4:31Speaker 2: you've got the insulin volumes coming through. So you've got
- 4:34Speaker 2: the benefit of increased volumes and output and reduced costs.
- 4:38Speaker 2: And that's a big driver. And I think we've got
- 4:41Speaker 2: it that that's going to be the main profit driver,
- 4:44Speaker 2: gross driver in 2027.
- 4:46Speaker 1: You've had quite a lot of, I think, what they
- 4:47Speaker 1: often call corporate activity over the last year. And the
- 4:51Speaker 1: MRNA thing was a major issue. You describe yourself at
- 4:54Speaker 1: an inflection point. Why do you say that for where
- 4:58Speaker 1: your company is right now?
- 5:00Speaker 2: Look, I think it's an inflection point. I think we've
- 5:02Speaker 2: got our sterile facilities at the right place, so we've
- 5:06Speaker 2: now got the cost base right. So whatever volumes you
- 5:08Speaker 2: get in there now will be highly incremental, and you've
- 5:11Speaker 2: seen that in our guidance for 2027. I think the
- 5:15Speaker 2: other big, you know, obviously we've got the commercial farmer business,
- 5:19Speaker 2: which has now got the Munjara in, and we're going
- 5:21Speaker 2: to be now hopefully getting the tailwind of the GLP-1
- 5:25Speaker 2: generics coming in. And then we've also got a huge
- 5:29Speaker 2: benefit from our, you know, obviously we've got no debt
- 5:32Speaker 2: in the books anymore. We're sitting with cash. And so
- 5:35Speaker 2: we're going to save over a billion rand of interest
- 5:37Speaker 2: next year. So if you take the profit growth and
- 5:39Speaker 2: the interest, our earnings growth is going to be quite
- 5:43Speaker 2: substantial in 2027. So we think we are at an
- 5:47Speaker 2: inflection point to grow earnings sustainably in the next year
- 5:50Speaker 2: and in the medium term.
- 5:53Speaker 1: Sean, thanks so much. Really appreciated. Sean Caposorio is the
- 5:57Speaker 1: Chief Financial Officer at the Aspen Group.